Methods of inducing responsiveness to anti-angiogenic agent
AssigneeVascular Biogenics Ltd.
InventorsAndrea Rachel LEUBITZ, Naamit SHER, Erez FEIGE, Eyal BREITBART
Life of this patent
Estimating the term…
Abstract
The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a F AS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.
Claims21
-51. (canceled)
A method of inducing apoptosis of an endothelial cell in a tumor of a subject in need thereof comprising:
- (i) administering to the subject a vector which comprises a Fas-chimera gene operably linked to an endothelial cell-specific promoter, wherein the responsiveness of the subject to a VEGF antagonist is increased after the administration of the vector, and
- (ii) administering a VEGF antagonist to the subject, wherein the tumor size or tumor growth in the subject is reduced after administration of the VEGF antagonist.
A method of inhibiting or reducing angiogenesis in a tumor of a subject in need thereof comprising:
- (i) administering to the subject a vector which comprises a Fas-chimera gene operably linked to an endothelial cell-specific promoter, wherein the responsiveness of the subject to a VEGF antagonist is increased after the administration of the vector, and
- (ii) administering a VEGF antagonist to the subject, wherein the disease or condition in the subject is treated after administration of the VEGF antagonist.
A method of identifying a candidate for a VEGF antagonist therapy comprising:
- (i) measuring a tumor size of a subject who is diagnosed as having a tumor prior to administering a vector which comprises a Fas-chimera gene operably linked to an endothelial cell specific promoter to the subject and
- (ii) measuring progression of the tumor after the administration of the vector,
- wherein the subject is identified as a candidate after the tumor is progressed.
Dependencies are inferred from the claim text.